Mirtazapin Teva B.V (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapin Teva B.V, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral formulation for oral use. It is indicated for the treatment of major depressive disorder in adult patients and works by modulating neurotransmitter activity to improve mood.

GNH USA supplies Mirtazapin Teva B.V as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under stringent quality assurance protocols.

Mirtazapine is used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves functional outcomes. - Depressive symptoms with comorbid anxiety: may alleviate mood disturbances and anxiety features. - Treatment‑resistant depression (adjunct therapy): can be added when first‑line agents are insufficient.

Common Side Effects: - Sedation or drowsiness - Increased appetite and weight gain - Dry mouth - Constipation - Dizziness - Peripheral edema

Serious or Rare Side Effects: - Agranulocytosis or severe neutropenia - Seizures - Suicidal thoughts or behavior - Severe hypersensitivity reactions (e.g., Stevens‑Johnson syndrome) - Hepatic dysfunction - Orthostatic hypotension

Mirtazapine should be prescribed after a thorough psychiatric assessment and with ongoing monitoring. - Suicidality: monitor for emergence or worsening of suicidal thoughts, especially early in treatment. - Hepatic impairment: use with caution and consider dose adjustment in patients with liver disease. - Abrupt discontinuation: taper gradually to avoid withdrawal symptoms. - Elderly patients: start at low dose and monitor for excessive sedation or falls. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirtazapine may interact with several other medicines, requiring careful management.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of serotonin syndrome. - CNS depressants (e.g., benzodiazepines, opioids): additive sedation. - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirtazapine levels.

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): monitor for serotonin syndrome. - Antihistamines: may enhance sedative effect. - Alcohol: can increase central nervous system depression. - Carbamazepine: may reduce mirtazapine exposure.